Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction
Executive Summary
Launch comes immediately after FDA approval of Dr. Reddy's and Mylan ANDAs while Indivior appeals district court ruling of non-infringement; Mylan settlement may delay its entry.
You may also be interested in...
Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market
US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.
Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market
US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.
US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On
Dr Reddy’s can re-launch its generic version of Indivior’s Suboxone (buprenorphine/naloxone) sublingual film in the US following a crucial court ruling that has gone its way. Indivior faces significant turbulence ahead if a generic entry materializes soon.